Bolt Biotherapeutics Q2 2026: Cash Runway Into Q1 2027, BDC-4182 Data Expected With Q3 Results
BOLT is trading near its 52-week low of $3.75 (6.1% above the low) on light trading volume (0.2× avg).
Summary
Bolt Biotherapeutics reported Q2 2026 results with $18.1M in cash, funding operations into Q1 2027. Initial clinical data from the BDC-4182 Phase 1/2 study is expected with Q3 2026 results.
Key Events · Earnings and Guidance · BOLT
-
Q2 2026 Financial Results
Net loss of $7.7 million ($4.57 per share) on collaboration revenue of $5,000. R&D expenses fell to $5.1 million from $7.5 million a year ago, reflecting restructuring and lower activity.
-
Cash Runway Into Q1 2027
Cash, equivalents, and marketable securities totaled $18.1 million as of June 30, 2026, expected to fund operations into the first quarter of 2027.
-
BDC-4182 Phase 1/2 Progress
The Phase 1/2 study in gastric and gastroesophageal cancers is enrolling patients in Cohort 4 at the 4.0 mg/kg dose level. Initial clinical data is expected with third-quarter 2026 results.
-
Cost Discipline After Restructuring
Operating expenses declined 24% year-over-year to $8.4 million, driven by lower R&D and G&A spending following prior restructuring actions.
Analysis · BOLT · Life Sciences
Bolt Biotherapeutics reported Q2 2026 results with $18.1 million in cash, enough to fund operations into the first quarter of 2027. The company is advancing its lead asset BDC-4182 in a Phase 1/2 trial for gastric and gastroesophageal cancers, with initial clinical data expected alongside third-quarter results. While the cash position is tight, the upcoming data readout is a potential catalyst that could validate the platform and attract partnership or financing interest. The net loss narrowed year-over-year, reflecting cost discipline after restructuring.
At the time of this filing, BOLT was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $3.75 to $7.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.